Global private equity and venture capital news and research

Posts Tagged ‘Omega Funds’

28 September 2015

Atlas Venture-led consortium helps fund latest Replimune cancer research

lab-217041_1280 Early-stage investment firm Atlas Venture has headed a group of investors to successfully close a $30m financing round for Oxford-based cancer therapeutics firm Replimune.

3 October 2014

Merck, Vertex and Temasek lead $30m round in Visterra

Visterra Merck Research Labs Venture Fund, Vertex Venture Holdings and Temasek have co-led a $30m Series B financing round in biotechnology company Visterra.

22 January 2014

Venture capital-backed Dicerna prices IPO at $11 to $13 per share

Venture capital-backed RNA interference-based therapeutics developer Dicerna Pharmaceuticals has priced its IPO at $11 to $13 per share.

1 August 2013

RA Capital backs mammoth $60m Series C round for RNA Interference

RA Capital has helped emerging pharmaceutical company RNA Interference close an enormous $60m Series C financing round.

23 July 2013

German medical device company JenaValve Technology inks $62.5m investment

German medical device company JenaValve Technology has raised $62.5m in a Series C venture round led by Belgium-based investment firm Gimv, alongside new investors including Beijing-based Legend Capital and healthcare-focused Omega Funds.

9 November 2012

Gates Foundation, Omega help Visterra close $26m Series A

Visterra, a developer of medicines to prevent and treat infectious diseases, has raised an additional $13m to complete a $26m Series A financing.

Legals & Terms of UsePrivacy Policy

AltAssets is registered as a trademark of Investor Networks Limited (06695690).
Registered Office: WeWork 4001, 1 Fore Street, London, EC2Y 5EJ
Content is © AltAssets 2000-2016